Correlation of Anti-CCP With Disease Activity and Its Impact on Biological Response in PsA in Iraqi Patients
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Pfizer
- Enrollment
- 127
- Locations
- 1
- Primary Endpoint
- Change From Baseline in Disease Activity in Psoriatic Arthritis (DAPSA) Score at Month 12
Study Overview
Brief Summary
This study is to evaluate the local data in Iraqi patients with psoriatic arthritis on Enbrel treatment with positive Anti-Cyclic Citrullinated Peptide using data from the Rheumatologist in Baghdad Teaching Hospital registry.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosed PsA patients.
- •≥18 years of age
- •Have not received previous biological treatment
Exclusion Criteria
- •Previous use of other biological treatments.
- •Etanercept use for less than 1 year duration.
Arms & Interventions
Patients with psoriatic arthritis
Iraqi patients diagnosed with psoriatic arthritis that receive Enbrel as treatment for disease
Intervention: Enbrel (Drug)
Outcomes
Primary Outcomes
Change From Baseline in Disease Activity in Psoriatic Arthritis (DAPSA) Score at Month 12
Time Frame: Baseline, Month 12
DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), C-reactive protein (CRP) level (milligram per deciliter \[mg/dL\]), participant assessment of pain (0 to 10 centimeter \[cm\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and participant's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0= excellent and 10= poor). A higher DAPSA score indicated more active disease activity. The assessment did not have a score range with an upper or lower bound. The outcome measure compared response between anti-cyclic citrullinated peptide positive and negative participants.
Change From Baseline in Disease Activity in Psoriatic Arthritis (DAPSA) Score at Month 1
Time Frame: Baseline, Month 1
DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), C-reactive protein (CRP) level (milligram per deciliter \[mg/dL\]), participant assessment of pain (0 to 10 centimeter \[cm\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and participant's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0= excellent and 10= poor). A higher DAPSA score indicated more active disease activity. The assessment did not have a score range with an upper or lower bound. The outcome measure compared response between anti-cyclic citrullinated peptide positive and negative participants.
Secondary Outcomes
No secondary outcomes reported